Key result
TCW trial evaluates FFR-guided PCI plus TAVI versus CABG plus SAVR in severe CAD and AS.
Why the study?
No dedicated prospective trial has evaluated outcomes of percutaneous versus surgical treatment in patients with severe aortic stenosis and multivessel or advanced coronary artery disease.
Does FFR-guided PCI and TAVI provide noninferior outcomes compared to combined CABG and SAVR in patients ≥ 70 years with severe AS and multivessel or advanced CAD?
RCT (n=328)
Open-label
1:1
Yes
Does FFR-guided PCI and TAVI provide noninferior outcomes compared to combined CABG and SAVR in patients ≥ 70 years with severe AS and multivessel or advanced CAD?
The TCW trial will provide the first prospective randomized evidence comparing a fully percutaneous approach (FFR-guided PCI and TAVI) to conventional surgery (CABG and SAVR) in older patients with severe aortic stenosis and advanced coronary artery disease.
Answers are grounded in this paper and cite their sources.
Question of noninferiority remains open for elderly patients with severe AS and advanced CAD; TCW trial will deliver first randomized comparison.
BACKGROUND: Patients with severe aortic stenosis (AS) frequently present with concomitant obstructive coronary artery disease (CAD). In those, current guidelines recommend combined coronary artery bypass grafting (CABG) and surgical aortic valve replacement (SAVR) as the preferred treatment option, although this surgical approach is associated with a high rate of clinical events. Combined transcatheter aortic valve implantation (TAVI) and percutaneous coronary intervention (PCI) with or without FFR have evolved as a valid alternative for cardiac surgery in patients with AS and multivessel or advanced CAD. To date, no dedicated trial has prospectively evaluated the outcomes of a percutaneous versus surgical treatment for patients with both severe AS and CAD. AIMS: To investigate whether fractional-flow reserve (FFR)-guided PCI and TAVI is noninferior to combined CABG and SAVR for the treatment of severe AS and multivessel or advanced CAD. METHODS: The Transcatheter Valve and Vessels (TCW) trial (clinicaltrial.gov: NCT03424941) is a prospective, randomized, controlled, open label, international trial. Patients ≥ 70 years with severe AS and multivessel (≥ 2 vessels) or advanced CAD, deemed feasible by the heart team for both; a full percutaneous or surgical treatment, will be randomised in a 1:1 fashion to either FFR-guided PCI followed by TAVI (intervention arm) vs. CABG and SAVR (control arm). The primary endpoint is a patient-oriented composite of all-cause mortality, myocardial infarction, disabling stroke, unscheduled clinically-driven target vessel revascularization, valve reintervention, and life threatening or disabling bleeding at 1 year. The TCW trial is powered for noninferiority, and if met, superiority will be tested. Assuming a primary endpoint rate of 30% in the CABG-SAVR arm, with a significance level α of 5%, a noninferiority limit delta of 15% and a loss to follow-up of 2%, a total of 328 patients are needed to obtain a power of 90%. The primary endpoint analysis is performed on an intention-to-treat basis. SUMMARY: The TCW Trial is the first prospective randomized trial that will study if a less invasive percutaneous treatment for severe AS and concomitant advanced CAD (i.e., FFR-guided PCI-TAVI) is noninferior to the guidelines recommended approach (CABG-SAVR).
No takes yet. Share an insight, caveat, or question.
Kedhi et al. (2024) conducted an RCT in Severe aortic stenosis and multivessel or advanced coronary artery disease (n=328). FFR-guided PCI followed by TAVI vs. CABG and SAVR was evaluated on Patient-oriented composite of all-cause mortality, myocardial infarction, disabling stroke, unscheduled clinically-driven target vessel revascularization, valve reintervention, and life threatening or disabling bleeding at 1 year. The TCW trial will randomize 328 patients to investigate whether FFR-guided PCI and TAVI is noninferior to CABG and SAVR for severe aortic stenosis and advanced coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: